Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | CCKBR | P32239 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | DHFR | P00374 | 3/20 | 0.35 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828313 | 0.89 | L3MBTL1 (0.45) | L3MBTL1KMT2ACCKBRPOLBGLO1 | |
| SCHEMBL22828282 | 0.84 | ALDH1A1 (0.40) | KMT2AALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL22828141 | 0.79 | CHRNB2 (0.40) | L3MBTL1KMT2AALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL22828289 | 0.75 | ALDH1A1 (0.38) | KMT2AALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL22828124 | 0.74 | ALDH1A1 (0.40) | KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL31229021 | 0.74 | L3MBTL1 (0.44) | L3MBTL1KMT2ACCKBRPOLBGLO1 | |
| SCHEMBL22828287 | 0.74 | CHRNB2 (0.36) | ALDH1A1HSD17B10MAPTSMN1; SMN2 | |
| SCHEMBL22828281 | 0.73 | UTS2R (0.44) | L3MBTL1ALDH1A1MAPT | |
| SCHEMBL22828137 | 0.72 | DPP7 (0.36) | KMT2AALDH1A1HSD17B10 | |
| SCHEMBL22828143 | 0.72 | UTS2R (0.42) | ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377420-B2 | Compositions and methods for making donor-acceptor azetines | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200399214-A1 | COMPOSITIONS AND METHODS FOR MAKING DONOR-ACCEPTOR AZETINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377420-B2 | Compositions and methods for making donor-acceptor azetines | AZI2, AAAS, ZRANB2 | L3MBTL1 1033/4885KMT2A 2097/4885CCKBR 1668/4885 |
| US-20200399214-A1 | COMPOSITIONS AND METHODS FOR MAKING DONOR-ACCEPTOR AZETINES | AZI2, AAAS, ZRANB2 | L3MBTL1 1033/4885KMT2A 2097/4885CCKBR 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.